Tysabri and PML: What Patients in Virginia Should Know About Monitoring

Latest update (2026-07)

From General Health Information to Targeted Risk Management

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Understanding the latest research and monitoring guidelines is essential for managing this risk. Building on decades of medical knowledge about immune-modulating therapies, this page provides a neutral overview of current PML monitoring recommendations for Tysabri patients.

Medical Evidence and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations, including the statute of limitations, is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised patients and is caused by the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation can include progressive neurological deficits such as weakness, vision changes, speech difficulties, and cognitive decline. Diagnosis often involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The timeline between Tysabri exposure and documented PML harm can vary, with cases reported after a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period is a key factor in both medical monitoring and legal claims. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow JC virus reactivation and uncontrolled replication in the brain, leading to PML. The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment and understanding of risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals must monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations and Statute of Limitations in Virginia

Regarding the adequacy of warnings, the boxed warning and prescribing information clearly state the PML risk and risk factors. However, for patients who developed PML, questions may arise about whether the warnings were sufficient given the severity of the outcome and the need for timely intervention. Settlement considerations for affected patients in Virginia involve evaluating the statute of limitations, which generally requires filing a claim within a certain period after the injury is discovered or should have been discovered. In Virginia, the statute of limitations for personal injury claims is typically two years from the date of injury, but this can be complex in PML cases due to the delayed onset and diagnosis. Patients should consult with legal counsel experienced in pharmaceutical litigation to assess their specific circumstances. In summary, Tysabri-associated PML is a serious adverse event with established risk factors and a known latency period. For Virginia patients, the medical evidence underscores the importance of monitoring and early intervention, while legal considerations require prompt action within the applicable statute of limitations. The adequacy of warnings and the timeline between exposure and harm are central to any settlement-related discussions. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Virginia?

In Virginia, the statute of limitations for personal injury claims is typically two years from the date of injury. However, for PML cases, the injury may not be discovered until years after exposure due to the latency period. The clock may start when the injury is discovered or should have been discovered. It is crucial to consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline for your specific case.

What are the risk factors for developing PML from Tysabri?

The three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

Related Articles

References

  1. Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Provide your details below to see if you qualify.

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.